Inhibition of Human Colon Cancer Growth by Antibody-Directed Human LAK Cells in SCID Mice
- 5 March 1993
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 259 (5100) , 1460-1463
- https://doi.org/10.1126/science.8451642
Abstract
Advanced human colon cancer does not respond to lymphokine-activated killer (LAK) cells. In order to direct cytotoxic cells to the tumor, human LAK cells linked with antibodies to a tumor cell surface antigen were tested with established hepatic metastases in severe combined immunodeficient (SCID) mice. These cells had increased uptake into the tumor and suppression of tumor growth as compared with LAK cells alone, thereby improving the survival of tumor-bearing mice. Thus, tumor growth can be inhibited by targeted LAK cells, and SCID mice can be used to test the antitumor properties of human effector cells.Keywords
This publication has 25 references indexed in Scilit:
- Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid MouseImmunological Reviews, 1991
- Fc ReceptorsAnnual Review of Immunology, 1991
- The SCID Mouse Mutant: Definition, Characterization, and Potential UsesAnnual Review of Immunology, 1991
- Function and heterogeneity of human Fc receptors for immunoglobulin G.Journal of Clinical Investigation, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and FunctionScience, 1988
- Transfer of a functional human immune system to mice with severe combined immunodeficiencyNature, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Effect of herpesvirus infections on T-lymphocyte subpopulations and blastogenic responses in renal transplant recipients receiving cyclosporineClinical Immunology and Immunopathology, 1986
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982